Concurrent hormone and radiation therapy in patients with breast cancer: what is the rationale?

The Lancet Oncology

Volumn 10, Issue 1, 2009, Pages 53-60

  Chargari, Cyrus ^a   Toillon, Robert Alain ^b   MacDermed, Dhara ^c   Castadot, Pierre ^d   Magné, Nicolas ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c UNIVERSITY OF CHICAGO   (United States)

^d JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; COBALT 60; CYCLIN DEPENDENT KINASE INHIBITOR 1; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PROGESTERONE RECEPTOR; PROTEIN P53; RETINOBLASTOMA PROTEIN; TAMOXIFEN;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST SURGERY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL DEATH; CELL KINETICS; CELL PROLIFERATION; CLINICAL TRIAL; CYTOTOXICITY; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG POTENTIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRANULOCYTOPENIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; IONIZING RADIATION; LUNG FIBROSIS; MEDICAL RESEARCH; NONHUMAN; OVERALL SURVIVAL; PARTIAL MASTECTOMY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RADIATION PNEUMONIA; RADIOSENSITIVITY; REVIEW; SKIN MANIFESTATION; TREATMENT OUTCOME; TUMOR CELL;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL CYCLE; COMBINED MODALITY THERAPY; ESTRADIOL; FEMALE; HUMANS; RADIATION TOLERANCE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA;

EID: 57749187910     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70333-4     Document Type: Review

References (73)

1. Lin N.U., and Winer E.P. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol 26 (2008) 798-805
2. Fisher B., Costantino J., Redmond C., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumours. N Engl J Med 320 (1989) 479-484
3. Dalberg K., Johansson H., Johansson U., and Rutqvist L.E. A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery: Stockholm Breast Cancer Study Group. Cancer 82 (1998) 2204-2211
4. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer: Swedish Breast Cancer Cooperative Group. J Natl Cancer Inst 88 (1996) 1543-1549
5. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467
6. Schmidberger H., Hermann R.M., Hess C.F., and Emons G. Interactions between radiation and endocrine therapy in breast cancer. Endocr Relat Cancer 10 (2003) 375-388
7. Hoeller U., Borgmann K., Feyer P., Souchon R., and Organgruppe "Mammakarzinom" der DEGRO. On the interaction of adjuvant radiotherapy and tamoxifen treatment for breast cancer. Strahlenther Onkol 183 (2007) 535-544
8. Fodor J. Interactions between radiation and hormonal therapy in breast cancer: simultaneous or sequential treatment. Orv Hetil 147 (2006) 121-125
9. Azria D., Ozsahin M., Gligorov J., et al. How to combine hormone therapy and radiation treatment in adjuvant breast cancer?. Cancer Radiother 12 (2008) 37-41
10. Bjornstrom L., and Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19 (2005) 833-842
11. Zhang Z., Kumar R., Santen R.J., and Song R.X. The role of adapter protein Shc in estrogen non-genomic action. Steroids 69 (2004) 523-529
12. Zhou Y., Eppenberger-Castori S., Eppenberger U., and Benz C.C. The NFκB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 12 (2005) 37-46
13. Kim I.A., Bae S.S., Fernandes A., et al. Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 65 (2005) 7902-7910
14. Kastan M.B., Zhan Q., El-Deiry W.S., et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71 (1992) 587-597
15. Sharpless N.E., and DePinho R.A. p53: good cop/bad cop. Cell 110 (2002) 9-12
16. Molinari A.M., Bontempo P., Schiavone E.M., et al. Estradiol induces functional inactivation of p53 by intracellular redistribution. Cancer Res 60 (2000) 2594-2597
17. Chen X., Shen B., Xia L., et al. Activation of nuclear factor κB in radioresistance of TP53-inactive human keratinocytes. Cancer Res 62 (2002) 1213-1221
18. Bradbury C.M., Markovina S., Wei S.J., et al. Indomethacin-induced radiosensitization and inhibition of ionizing radiation-induced NF-κB activation in HeLa cells occur via a mechanism involving p38 MAP kinase. Cancer Res 61 (2001) 7689-7696
19. Wang T., Zhang X., and Li J.J. The role of NF-κB in the regulation of cell stress responses. Int Immunopharmacol 2 (2002) 1509-1520
20. Magné N., Toillon R.A., Bottero V., et al. NF-kappaB modulation and ionizing radiation: mechanisms and future directions for cancer treatment. Cancer Lett 231 (2006) 158-168
21. Fisher B., Bryant J., Dignam J.J., et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumour recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 20 (2002) 4141-4149
22. Devriendt D., Ma Y., Kinnaert E., et al. Effect of low dose irradiation on oestrogen receptor level in MCF-7 breast cancer cells. Int J Cancer 96 (2001) 32-40
23. Toillon R.A., Magné N., Laïos I., et al. Estrogens decrease gamma-ray-induced senescence and maintain cell cycle progression in breast cancer cells independently of p53. Int J Radiat Oncol Biol Phys 67 (2007) 1187-1200
24. Essmann F., Engels I.H., Totzke G., Schulze-Osthoff K., and Jänicke R.U. Apoptosis resistance of MCF-7 breast carcinoma cells to ionizing radiation is independent of p53 and cell cycle control but caused by the lack of caspase-3 and a caffeine-inhibitable event. Cancer Res 64 (2004) 7065-7072
25. Xia L., Paik A., and Li J.J. p53 activation in chronic radiation-treated breast cancer cells: regulation of MDM2/p14ARF. Cancer Res 64 (2004) 221-228
26. Jones K.R., Elmore L.W., Jackson-Cook C., et al. p53-Dependent accelerated senescence induced by ionizing radiation in breast tumour cells. Int J Radiat Biol 81 (2005) 445-458
27. Kumar B., Joshi J., Kumar A., Pandey B.N., Hazra B., and Mishra K.P. Radiosensitization by diospyrin diethylether in MCF-7 breast carcinoma cell line. Mol Cell Biochem 304 (2007) 287-296
28. Ikeda K., and Inoue S. Estrogen receptors and their downstream targets in cancer. Arch Histol Cytol 67 (2004) 435-442
29. Lippman M., Bolan G., and Huff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 36 (1976) 4595-4601
30. Toillon R.A., Magné N., Laïos I., et al. Interaction between estrogen receptor alpha, ionizing radiation and (anti-) estrogens in breast cancer cells. Breast Cancer Res Treat 93 (2005) 207-215
31. Sutherland R.L., Taylor I.W., Reddel R.R., and Hall R.E. Effects of tamoxifen on the cell cycle kinetics of human mammary carcinoma cells in culture. J Cell Biochem 6 (1982) 1034
32. Osborne C.K., Boldt D.H., Clark G.M., and Trent J.M. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res 43 (1983) 3583-3585
33. Wazer D.E., Tercilla O.F., Lin P.S., and Schmidt-Ullrich R. Modulation in the radiosensitivity of MCF-7 human breast carcinoma cells by 17B-estradiol and tamoxifen. Br J Radiol 62 (1989) 1079-1083
34. Germain P., and Harbrioux G. Modulation of the estradiol-17 beta mitogenic effect on human breast cancer MCF-7 cells by serum albumin in defined medium. Anticancer Res 13 (1993) 1581-1585
35. Ichikawa A., Ando J., and Suda K. G1 arrest and expression of cyclin-dependent kinase inhibitors in tamoxifen-treated MCF-7 human breast cancer cells. Hum Cell 21 (2008) 28-37
36. Paulsen G.H., Strickert T., Marthinsen A.B., and Lundgren S. Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro. Acta Oncol 35 (1996) 1011-1019
37. Schmidt-Ullrich R.K., Valerie K., Chan W., Wazer D.E., and Lin P.S. Expression of oestrogen receptor and transforming growth factor-alpha in MCF-7 cells after exposure to fractionated irradiation. Int J Radiat Biol 61 (1992) 405-415
38. Schmidt-Ullrich R.K., Valerie K.C., Chan W., and McWilliams D. Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. Int J Radiat Oncol Biol Phys 29 (1994) 813-819
39. Sarkaria J., Miller E., Parker C., et al. 4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiated in vitro. Breast Cancer Res Treat 30 (1994) 159-165
40. Colletta A.A., Wakefield L.M., Howell F.V., et al. Anti-oestrogens induce the secretion of active transforming growth factor beta from human fetal fibroblasts. Br J Cancer 62 (1990) 405-409
41. Charlier C., Chariot A., Antoine N., Merville M.P., Gielen J., and Castronovo V. Tamoxifen and its active metabolite inhibit growth of estrogen receptor-negative MDA-MB-435 cells. Biochem Pharmacol 49 (1995) 351-358
42. Knabbe C., Lippman M.E., Wakefield L.M., Derynk R., and Dickson R.B. Evidence that transforming growth factor beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48 (1987) 417-428
43. Biswas S., Guix M., Rinehart C., et al. Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 117 (2007) 1305-1313
44. Yoo Y.A., Kim Y.H., Kim J.S., and Seo J.H. The functional implications of Akt activity and TGF-beta signaling in tamoxifen-resistant breast cancer. Biochim Biophys Acta 1783 (2008) 438-447
45. Spom M.B., Roberts A.B., Wakefield L.M., and Assoian R.K. Transforming growth factor-beta: biological function and chemical structure. Science 233 (1986) 532-534
46. Border W.A., and Noble N.A. Transforming growth factor beta in tissue fibrosis. N Engl J Med 331 (1994) 1286-1292
47. Kantorowitz D.A., Thompson H.J., and Furmanski P. Effect of conjoint administration of tamoxifen and high-dose radiation on the development of mammary carcinoma. Int J Radiat Oncol Biol Phys 26 (1993) 89-94
48. Sarkaria J.N., Fowler J.F., Lindstrom M.J., Jordan V.C., and Mulcahy R.T. The decreased influence of overall treatment time on the response of human breast tumour xenografts following prolongation of the potential doubling time (Tpot). Int J Radiat Oncol Biol Phys 31 (1995) 833-840
49. Butta A., MacLennan K., Flanders K.C., et al. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 52 (1992) 4261-4264
50. Fisher B., Digman J., Wolmark N., et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353 (1999) 1993-2000
51. Pierce L.J., Hutchins L.F., Green S.R., et al. Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol 23 (2005) 24-29
52. Ahn P.H., Vu H.T., Lannin D., et al. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol 23 (2005) 17-23
53. Whelan T., and Levine M. Radiation therapy and tamoxifen: concurrent or sequential? That is the question. J Clin Oncol 23 (2005) 1-4
54. Harris E.E., Christensen V.J., Hwang W.T., Fox K., and Solin L.J. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol 23 (2005) 11-16
55. Bentzen S.M., and Yarnold J.R. Sequential or concurrent tamoxifen and radiotherapy: to see or not to see-that is the question!. J Clin Oncol 23 (2005) 6266-6267
56. Azria D., Pelegrin A., Dubois J.B., Mirimanoff R.O., and Ozsahin M. Radiation therapy and tamoxifen: concurrent or sequential? It's no longer the question!. J Clin Oncol 23 (2005) 4239-4241
57. Bentzen S.M., Skoczylas J.Z., Overgaard M., and Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst 88 (1996) 918-922
58. Wennberg B., Gagliardi G., Sundbom L., et al. Early response of lung in breast cancer irradiation: Radiologic density changes measured by CT and symptomatic radiation pneumonitis. Int J Radiat Oncol Biol Phys 52 (2002) 1196-1206
59. Koc M., Polat P., and Suma S. Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients. Radiother Oncol 64 (2002) 171-175
60. Huang E., Wang C., Chen H., et al. Multivariate analysis of pulmonary fibrosis after electron beam irradiation for postmastectomy chest wall and regional lymphatics: Evidence for nondosimetric factors. Radiother Oncol 57 (2000) 91-96
61. Wazer D., DiPetrillo T., Schmidt-Ulrich R., et al. Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol 10 (1992) 356-363
62. Fowble B., Fein D., Hanlon A., et al. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer. Int J Rad Oncol Biol Phys 35 (1996) 669-677
63. Azria D., Gourgou S., Sozzi W.J., et al. Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. Br J Cancer 91 (2004) 1251-1260
64. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrazole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
65. Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian tamoxifen anastrozole trial. J Clin Oncol 23 (2005) 5138-5147
66. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
67. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
68. Kaufmann M., Jonat W., Hilfrich J., et al. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 25 (2007) 2664-2670
69. The Arimidex, Tamoxifen, Alone or in Combination Trialists' Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7 (2006) 633-643
70. Coombes R.C., Hall E., Gibson L.J., et al. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
71. Azria D., Larbouret C., Cunat S., et al. Letrozole sensitizes breast cancer cells to ionizing radiation. Breast Cancer Res 7 (2005) 156-163
72. Bollet M.A., Kirova Y.M., Antoni G., et al. Responses to concurrent radiotherapy and hormone-therapy and outcome for large breast cancers in post-menopausal women. Radiother Oncol 85 (2007) 336-345
73. Nakatani K., Matsumoto M., Ue H., et al. Erythema multiforme after radiotherapy with aromatase inhibitor administration in breast-conservation treatment for breast cancer. Breast Cancer 15 (2008) 321-323